September 24, 2026

MALMÖ, Sweden, September 24, 2026 (GLOBE NEWSWIRE) — Oatly Group AB (publ) (Nasdaq: OTLY), the world’s original and largest oat drink company, has today published a prospectus.

On September 30, 2025, Oatly Group AB (publ) (“Oatly”) issued senior secured floating rate bonds in a total amount of SEK 1,700 million (the “Nordic Bonds”). In accordance with the terms and conditions for the Nordic Bonds, Oatly intends to apply for admission to trading of the Nordic Bonds on Nasdaq Stockholm’s Corporate Bond List. In connection with the application for admission to trading of the Nordic Bonds, Oatly has prepared a prospectus which today, on September 24, 2026, has been approved and registered by the Swedish Financial Supervisory Authority. Admission to trading of the Nordic Bonds on Nasdaq Stockholm’s Corporate Bond List is expected to take place on or about September 28, 2026.

The prospectus is available on the Company’s corporate website: Investor Relations | Oatly Group AB

Pursuant to the Transparency Directive (2004/109/EC) and the Swedish Securities Market Act (2007:528) (Sw. lagen (2007:528) om värdepappersmarknaden), Oatly has chosen Sweden as its home member state (Sw. hemmedlemsstat) in connection with the application for admission to trading of the Nordic Bonds.

About Oatly
We are the world’s original and largest oat drink company. For over 30 years, we have exclusively focused on developing expertise around oats: a global power crop with inherent properties. Our commitment to oats has resulted in core technical advancements that enabled us to unlock the breadth of the dairy portfolio, including alternatives to milks, ice cream, yogurt, cooking creams, spreads and on-the-go drinks. Headquartered in Malmö, Sweden, the Oatly brand is available in more than 60 countries globally.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements regarding our financial outlook for 2026, profitability improvement, profitable growth in 2026, long-term growth strategy, expected capital expenditures, anticipated returns on our investments, anticipated supply chain performance, anticipated impact of our improvement plans, anticipated impact of our decision to discontinue construction of certain production facilities, plans to achieve profitable growth and anticipated cost savings and efficiencies as well as statements that include the words “expect”, “intend”, “plan”, “believe”, “project”, “forecast”, “estimate”, “may”, “should”, “anticipate”, “will”, “aim”, “potential”, “continue”, “is/are likely to” and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: we have a history of losses, and we may be unable to achieve or sustain profitability, including due to elevated inflation and increased costs for transportation, energy, and materials; our future business, financial condition and results of operations may be adversely affected by reduced or limited availability of oats and other raw materials and ingredients, which meet our quality standards, that our limited number of suppliers are able to sell to us; a failure to obtain necessary capital when needed on acceptable terms, or at all, may force us to delay, limit, reduce or terminate our product manufacturing and development and other operations; the primary components of all our products are manufactured in our production facilities, and damage or disruption at these facilities has in the past harmed, and may in the future harm, our business; our brand or reputation may be harmed due to real or perceived quality, food safety, nutrition or sustainability issues with our products, which could have an adverse effect on our business, reputation, financial condition and results of operations; food safety and food-borne illness incidents or other safety concerns have led to product recalls, and may materially adversely affect our business, financial condition and results of operations by exposing us to lawsuits or regulatory enforcement actions in the future, increasing our operating costs and reducing demand for our product offerings; failure by our suppliers of raw materials or co-manufacturers to comply with food safety, environmental or other laws and regulations, or with the specifications and requirements of our products, may disrupt our supply of products and adversely affect our business; we may not be able to compete successfully in our highly competitive markets; consolidation of customers, the loss of a significant customer or the decrease of sales from a significant customer, could negatively impact our sales and profitability; sales of our oatmilk varieties contribute a significant portion of our revenue and a reduction in such sales would have an adverse effect on our business, financial condition and results of operations; we continue to pursue largely an asset-light business model blending a heavy reliance on our co-manufacturing partners in addition to in-house capacity expansions where appropriate; our strategic partnerships with our co-manufacturers may not be successful, which could adversely affect our operations and manufacturing strategy; failure by our logistics providers to deliver our products on time, or at all, could result in lost sales; we may not successfully ramp up operations at any of our or our co-manufacturing partners’ facilities, or these facilities may not operate in accordance with our expectations; if we fail to effectively expand our processing, manufacturing and production capacity through existing facilities or acceptable co-manufacturing partners as we continue to grow and scale our business to a steady operating level, our business, financial condition, results of operations and our brand reputation could be harmed; if we fail to develop and maintain our brand, our business could suffer; failure to develop or introduce new products or successfully improve existing products may adversely affect our ability to continue to grow; if we fail to cost-effectively acquire new customers and consumers or retain our existing customers and consumers, or if we fail to derive revenue from our existing customers consistent with our historical performance, our business could be materially adversely affected; consumer preferences for our products are difficult to predict and may change, and, if we are unable to respond quickly to new trends, our business may be adversely affected; if we fail to manage our future growth effectively, including maintenance of our workforce, our business, financial condition and results of operations could be materially adversely affected; we have recognized impairment charges for long-lived assets and other exit costs in connection with our production facilities, and we may need to recognize further costs in the future, which could adversely impact our business, financial condition and results of operations; we are subject to risks related to sustainability (including environmental, climate change and broader corporate social responsibility matters), which may materially adversely affect our business as a result of lawsuits, regulatory investigations and enforcement actions, complaints concerning our disclosures, impacts on our operations and supply chain (particularly in connection with the physical impacts of climate change), and impacts on our brand and reputation; we rely on information technology systems and any inadequacy, failure or interruption of, or cybersecurity incidents affecting, those systems may harm our reputation and ability to effectively operate our business; a cybersecurity incident or other technology disruptions could negatively impact our business and our relationships with customers; to remain competitive, we believe we will need to adopt artificial intelligence and other machine learning technologies; our customer agreements do not contain long-term commitments and do not require our customers to continue purchasing products from us and this may negatively impact our business or financial condition; we may face difficulties as we expand our operations into countries in which we have no prior operating experience; the strategic review of the Company’s Greater China operations may not be successful; our operations in China could expose us to substantial business, regulatory, political, financial and economic risks; the international nature of our business subjects us to additional global economic and geopolitical risks; if we fail to comply with trade compliance and economic sanctions laws and regulations of the United States (the “U.S.”), the EU and other applicable international jurisdictions, it could materially adversely affect our reputation and results of operations; some of our debt agreements contain a floating interest rate component and as a result, an increase in market interest rates will increase our future interest payments under such agreements; our international operations expose us to the risk of fluctuations in currency exchange rates; we maintain cash and cash equivalents at financial institutions, often in amounts exceeding insured limits, and the failure of one or more of these institutions could result in a loss of deposits and adversely affect our liquidity or ability to raise capital; packaging costs are volatile and may rise significantly, which may negatively impact the profitability of our business; fluctuations in our results of operations may impact, and may have a disproportionate effect on, our overall financial condition and results of operations; litigation or legal proceedings could expose us to significant liabilities or costs and have a negative impact on our reputation or business; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all; failure to retain our senior management or to attract, train and retain qualified employees may adversely affect our operations or our ability to grow successfully; if we cannot maintain our company culture or focus on our mission as we grow, our success and our business and competitive position may be harmed; our insurance may not provide adequate levels of coverage against claims or we may be unable to find insurance with sufficient coverage at a reasonable cost; disruptions in the worldwide economy may adversely affect our business, financial condition and results of operations; our business is affected by macroeconomic conditions, including international tariffs and trade wars, rising inflation, interest rates and supply chain constraints; we are subject to risks inherent to organizations with international operations, which could harm our business, and global conflicts, including the ongoing conflict in the Middle East; legal claims, government investigations or other regulatory enforcement actions could subject us to civil and criminal penalties; our operations are subject to U.S., EU, China and other laws and regulations, and there is no assurance that we will be in compliance with all applicable laws and regulations; changes in existing laws or regulations, or the adoption of new laws or regulations may increase our costs and otherwise adversely affect our business, financial condition and results of operations; we are subject to stringent environmental regulation and potentially subject to environmental litigation, proceedings and investigations; we may not be able to protect, enforce or defend our intellectual property and other proprietary rights adequately, which may impact our commercial success; we have incurred substantial indebtedness that may decrease our business flexibility, access to capital, and/or increase our future borrowing costs; and the other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 13, 2026, and our other filings with the SEC as such factors may be updated from time to time. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Oatly disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.

For further information:

Contact person
John Baumgartner, CFA, Vice President, Investor Relations
E-mail: investors@oatly.com, press@oatly.com

Attachments

TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call Information
Participants may access the conference call live via webcast on the ‘Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) — LPL Financial Holdings Inc. (Nasdaq: LPLA) (the “Company”) today released its monthly activity report for August 2026.

Total client assets at the end of August were $2.60 trillion, an increase of $55.3 billion, or 2.2%, compared to the end of July. Advisory assets as a percentage of total assets increased to 60.8%, up from 57.8% a year ago.

Total organic net new assets (“NNA”) for August were $13.5 billion, translating to a 6.4% annualized growth rate.

Total client cash balances at the end of August were $54.4 billion, an increase of $0.1 billion compared to the end of July. Net buying in August was $13.8 billion.

(End of period $ in billions, unless noted) August   July   Change   August   Change  
2026   2026   M/M   2025   Y/Y  
Client Assets              
Advisory 1,582.5   1,544.2   2.5 % 1,308.3   21.0 %
Brokerage 1,019.4   1,002.4   1.7 % 955.3   6.7 %
Total Client Assets 2,601.9   2,546.6   2.2 % 2,263.5   15.0 %
               
Organic NNA              
Advisory 12.5   10.2   n/m   11.8   n/m  
Brokerage 0.9   (2.8 ) n/m   6.1   n/m  
Total Organic NNA 13.5   7.4   n/m   17.8   n/m  
               
Acquired NNA(1)              
Advisory 0.0   0.0   n/m   199.3   n/m  
Brokerage 0.0   0.0   n/m   75.7   n/m  
Total Acquired NNA 0.0   0.0   n/m   275.0   n/m  
               
Total NNA              
Advisory 12.5   10.2   n/m   211.1   n/m  
Brokerage 0.9   (2.8 ) n/m   81.7   n/m  
Total NNA 13.5   7.4   n/m   292.8   n/m  
               
Net brokerage to advisory conversions 1.7   1.9   n/m   2.1   n/m  
               
Client Cash Balances              
Insured cash account sweep 37.1   36.8   0.8 % 35.0   6.0 %
Deposit cash account sweep 15.1   15.0   0.7 % 12.2   23.8 %
Total Bank Sweep 52.2   51.8   0.8 % 47.2   10.6 %
Money market sweep 1.0   1.1   (9.1 %) 4.1   (75.6 %)
Total Client Cash Sweep Held by Third Parties 53.1   52.8   0.6 % 51.3   3.5 %
Client cash account 1.2   1.5   (20.0 %) 1.4   (14.3 %)
Total Client Cash Balances 54.4   54.3   0.2 % 52.7   3.2 %
               
Net buy (sell) activity 13.8   14.7   n/m   14.2   n/m  
               
               
Market Drivers              
S&P 500 Index (end of period) 7,686   7,490   2.6 % 6,460   19.0 %
Russell 2000 Index (end of period) 2,956   2,931   0.9 % 2,366   25.0 %
Fed Funds daily effective rate (average bps) 363   363   — % 433   (16.2 %)
               

Note: Totals may not foot due to rounding.
(1) In August 2025, includes Commonwealth assets as of 6/30/2025, assuming 90% retention. Based on unaudited preliminary financial information of Commonwealth. 

For additional information regarding these and other Company business metrics, please refer to the Company’s most recent earnings announcement, which is available in the quarterly results section of investor.lpl.com.

Contacts

Investor Relations
investor.relations@lplfinancial.com

Media Relations
media.relations@lplfinancial.com

About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 32,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $2.6 trillion in brokerage and advisory assets on behalf of approximately 8 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”) and LPL Enterprise, LLC (“LPL Enterprise”), both registered investment advisers and broker-dealers. Members FINRA/SIPC.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial or LPL Enterprise.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

SPRINGFIELD, Mo., Sept. 24, 2026 (GLOBE NEWSWIRE) — Great Southern Bancorp, Inc. (NASDAQ:GSBC), the holding company for Great Southern Bank, expects to report third quarter preliminary earnings after the market closes on Wednesday, October 21, 2026, and host a conference call on Thursday, October 22, 2026, at 2:00 p.m. Central Time (3:00 p.m. Eastern Time).

The call will be available live or later in a recorded version at the Company’s Investor Relations website, https://investors.greatsouthernbank.com.

Participants may register for the call here. While not required, it is recommended that participants join 10 minutes prior to the event start. Instructions are provided to ensure the necessary audio applications are downloaded and installed. Users can obtain these programs at no cost.

The Company will notify the public that third quarter 2026 results have been issued through a news release and will post the results to the Company’s Investor Relations website. The earnings release will also be available on the Securities and Exchange Commission’s (SEC) website, www.sec.gov, as an exhibit to a Current Report on Form 8-K that will be furnished by the Company to the SEC.

About Great Southern Bank

Headquartered in Springfield, Missouri, Great Southern offers a broad range of banking services to customers. The Company operates 87 retail banking centers in Missouri, Iowa, Kansas, Minnesota, and Nebraska and commercial lending offices in Atlanta, Charlotte, Chicago, Dallas, Denver, and Phoenix. The common stock of Great Southern Bancorp, Inc. is listed on the Nasdaq Global Select Market under the symbol “GSBC.”

CONTACT:

Kincade Ayers,
Investor Relations,
(616) 233-0500
GSBC@lambert.com

WINTER PARK, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) — CTO Realty Growth (NYSE: CTO) (the “Company”) announced today that it will report its financial and operating results for the third quarter of 2026 after the market closes on Tuesday, October 27, 2026. A conference call to discuss its financial and operating results is scheduled for Wednesday, October 28, 2026 at 9:00 AM ET.

A live webcast of the call will be available on the Investor Relations page of the Company’s website at www.ctoreit.com or at the link provided in the event details below. To access the call by phone, please go to the registration link provided in the event details below and you will be provided with dial-in details.

Event Details:  
Webcast: https://edge.media-server.com/mmc/p/fu529fsr
Registration: https://register-conf.media-server.com/register/BI7d08c73e0701499d94825c3c59fee239
   

We encourage participants to register and dial into the conference call at least fifteen minutes ahead of the scheduled start time. A replay of the earnings call will be archived and available online through the Investor Relations section of the Company’s website at www.ctoreit.com.

About CTO Realty Growth, Inc.

CTO Realty Growth, Inc. owns and operates high-quality, open-air shopping centers located primarily in the higher growth Southeast and Southwest markets of the United States. CTO also externally manages and owns a meaningful interest in Alpine Income Property Trust, Inc. (NYSE: PINE).

We encourage you to review our most recent investor presentation and supplemental financial information, which is available on our website at www.ctoreit.com.

CONTACT: Contact:
Investor Relations
ir@ctoreit.com

WINTER PARK, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) — Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”) announced today that it will report its financial and operating results for the third quarter of 2026 after the market closes on Thursday, October 22, 2026. A conference call to discuss its financial and operating results is scheduled for Friday, October 23, 2026 at 9:00 AM ET.

A live webcast of the call will be available on the Investor Relations page of the Company’s website at www.alpinereit.com or at the link provided in the event details below. To access the call by phone, please go to the link provided in the event details below and you will be provided with dial-in details.

Event Details:  
Webcast: https://edge.media-server.com/mmc/p/gx2epmx6
Registration:  https://register-conf.media-server.com/register/BIdda2983b5d4a42ac87f47a22c6553594
   

We encourage participants to register and dial into the conference call at least fifteen minutes ahead of the scheduled start time. A replay of the earnings call will be archived and available online through the Investor Relations section of the Company’s website at www.alpinereit.com.

About Alpine Income Property Trust, Inc.

Alpine Income Property Trust, Inc. (NYSE: PINE) is a publicly traded real estate investment trust that seeks to deliver attractive risk-adjusted returns and dependable cash dividends by investing in, owning and operating a portfolio of single tenant net leased commercial income properties that are predominately leased to high-quality publicly traded and credit-rated tenants. The Company also complements its income property portfolio by strategically investing in a select portfolio of commercial loan investments intended to deliver an attractive risk-adjusted return.

We encourage you to review our most recent investor presentation which is available on our website at http://www.alpinereit.com.

CONTACT: Contact:
Investor Relations
ir@alpinereit.com

RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Stifel 2026 Virtual Cardiometabolic Forum taking place on September 30, 2026.

Stifel 2026 Virtual Cardiometabolic Forum
Date:   Wednesday, September 30, 2026
Time:    12:00pm ET
Format:    Fireside Chat

A live webcast of this fireside chat can be accessed on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.

About Mineralys Therapeutics
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Contact:

Investor Relations investorrelations@mineralystx.com

GEORGE TOWN, Cayman Islands, Sept. 24, 2026 (GLOBE NEWSWIRE) — Bullish (NYSE:BLSH) and Equiniti today announced the formation of the Issuer Sponsored Token Coalition, a multi-stakeholder industry working group bringing together leading firms across brokerage, trading and market infrastructure to advance issuer-sponsored tokenized securities.

Alpaca, Apex Fintech Solutions and DriveWealth are among the first market infrastructure participants joining Bullish and Equiniti in the Coalition, which is being established to help develop the technical standards, market infrastructure and operating frameworks necessary for tokenized securities to scale alongside, and interoperate with, the existing capital markets ecosystem.

The Coalition is founded on the belief that the next generation of tokenized public securities should preserve the fundamental relationship between an issuer and its shareholders. Under an issuer-sponsored model, tokenized securities can be directly connected to the issuer’s authoritative shareholder register, helping preserve ownership rights, corporate-action entitlements and investor protections while enabling the benefits of blockchain-based market infrastructure.

The launch follows the U.S. Securities and Exchange Commission’s Sept. 17 Innovation Exemption, which permits limited onchain trading of U.S.-listed equities. The order requires venues to verify that a tokenized stock gives holders the same rights and privileges as the equivalent traditional share, which highlights the leadership role that ISTs are positioned to have as the new market evolves. The relief runs for five years, and the Commission is seeking public comment on how the framework should evolve.

“Tokenization will turn static, opaque assets into active, transparent digital shares. The architecture we establish now matters and that is why we are bringing together this group of leading firms to chart the course,” said Tom Farley, CEO of Bullish. “Public companies should remain at the center of the relationship with their shareholders as we combine the advantages of blockchain technology with the protections and market structure that make public markets work.”

The Coalition will focus initially on four areas:

  • Preserving issuer and shareholder rights: advancing a regulated model for tokenized securities that maintains the legal rights, corporate-action entitlements and investor protections associated with traditionally held shares.
  • Building interoperability: developing common technical and operational approaches that allow issuer-sponsored securities to move across traditional clearing and settlement infrastructure, blockchain networks, wrapped-token models and emerging entitlement-token frameworks.
  • Creating the infrastructure for adoption: addressing the regulatory, operational and commercial requirements surrounding issuance, transfer, settlement, custody and secondary-market trading.
  • Growing an open market ecosystem: bringing together issuers, broker-dealers, exchanges, transfer agents, custodians, market makers, liquidity providers and technology companies to support a scalable tokenized securities market.

The Coalition expects its work to include evaluation of blockchain and smart-contract architectures, development of interoperability standards, analysis of regulatory and compliance requirements, product prototyping and pilots, and engagement with policymakers, industry bodies and standards organizations. The group is intended to be open and non-exclusive, with additional market participants who share the vision invited to join over time.

“Tokenization creates an opportunity to connect issuers and investors in ways that weren’t possible with traditional market infrastructure,” said Arush Sehgal, Head of Digital Assets at Alpaca. “Getting it right means preserving shareholder rights and ensuring onchain markets remain connected to the markets they’re built on. We’re joining the Coalition to help advance the interoperability between traditional and onchain markets that allows tokenized equities and their traditional counterparts to be converted through Alpaca’s Instant Tokenization Network.”

“Tokenized securities will only scale if they preserve the relationships and protections that market participants rely on today,” said Travis McGhee, Global Head of Digital Markets at Apex Fintech Solutions. “Apex operates across issuers, broker-dealers and investors, so we see firsthand how important connective infrastructure is. We’re joining the Coalition to help advance standards that allow tokenized markets to scale responsibly.”

“Much of what’s marketed today as ‘tokenized equity’ isn’t equity at all. Investors think they own the share, and they don’t. That’s the gap this Coalition is built to close,” said Naureen Hassan, CEO of DriveWealth. “An issuer-sponsored model preserves real ownership with the same shareholder rights, voting and corporate-action entitlements investors have today, even as the rails move on-chain. Innovation and genuine ownership have never been competing goals. They’re both what make a market worth investing in, and we’re glad to help build it that way from the start.”

Bullish and Equiniti are developing infrastructure designed to support issuer-sponsored tokenized securities while maintaining an authoritative shareholder register and enabling interoperability with traditional capital-market infrastructure and blockchain-based markets. The Coalition expands that effort by bringing together participants responsible for many of the critical functions between issuers and investors.

Coalition members will convene with issuers and other capital-market leaders at the New York Stock Exchange on October 27 for a discussion focused on how public companies can approach tokenization, what infrastructure is required to support it, and how issuer-sponsored models can connect traditional securities markets with emerging blockchain-based rails.

Additional Coalition participants and initiatives will be announced in the coming weeks.

About the Issuer Sponsored Token Coalition

The Issuer Sponsored Token Coalition is a non-exclusive industry working group convened by Bullish and Equiniti to explore and advance the infrastructure, standards and commercial ecosystem required to support issuer-sponsored tokenized securities. Participants include firms across brokerage, exchanges, transfer agency, custody, liquidity, technology and other areas of market infrastructure. Participation in the Coalition is non-binding and does not require any participant to enter into a commercial arrangement, issue or list a security, provide liquidity or support any particular product.

Media Contact: media@bullish.com

About Bullish
Bullish (NYSE: BLSH) is an institutionally focused global digital asset platform that provides regulated market infrastructure and information services. This includes Bullish Exchange — an institutionally focused digital assets spot and derivatives exchange, integrating a high-performance central limit order book matching engine with automated market making to provide deep and predictable liquidity. Bullish Europe is regulated under MiCAR as a crypto asset service provider offering spot trading and custody services for digital assets.

Bullish is the parent company of CoinDesk, a leading provider of digital asset media and information services. CoinDesk’s offerings include: CoinDesk Indices — a collection of tradable proprietary and single-asset benchmarks and indices that track the performance of digital assets for global institutions in the digital assets and traditional finance industries; CoinDesk Data — a broad suite of digital asset market data and analytics, providing real-time insights into prices, trends and market dynamics; and CoinDesk Insights — a digital asset media and events provider and operator of coindesk.com, a digital media platform that covers news and insights about digital assets, the underlying markets, policy and blockchain technology.

In May 2026, Bullish agreed to acquire Equiniti in a $4.2 billion transaction to create the world’s leading transfer agent for tokenized securities. The combined platform is designed to span the full lifecycle of a tokenized security, from issuance and registry through to trading. The transaction is expected to close in January 2027, subject to customary closing conditions and required regulatory approvals.

For more information, please visit bullish.com and follow LinkedIn and X.

Use of Websites to Distribute Material Company Information
We use the Bullish Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the U.S. Securities and Exchange Commission (SEC) and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Sentences containing words such as “believe,” “intend,” “plan,” “may,” “will,” “expect,” “should,” “could,” “anticipate,” “estimate,” “predict,” “project,” or their negatives, or other similar expressions of a future or forward-looking nature generally should be considered forward-looking statements and include, without limitation, statements relating to the acquisition of Equiniti, the timing of, and our ability to obtain, maintain, and operate under, regulatory approvals, authorizations, licenses, registrations, and consents, future events or Bullish’s future financial or operating performance, business strategy, and potential market opportunity of Bullish, Equiniti or the combined companies, our plans and expectations related to tokenization and the growth and adoption of tokenized securities and blockchain technology, competition in our industry, the regulatory and legal environment, including regulatory proceedings or approvals, and general economic and business conditions. Such forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Bullish, are inherently uncertain and are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause results to differ from those expressed in our forward-looking statements include, but are not limited to, the satisfaction of the conditions to closing the acquisition of Equiniti in the anticipated timeframe or at all, the failure to obtain necessary regulatory approvals, the ability to realize the anticipated benefits of the combination, the ability to successfully integrate the business, litigation or regulatory actions related to the acquisition and combination, disruption from the acquisition and combination and its impact on our ability to grow our business and operations, including in new geographic locations, the costs or expenditures associated therewith, competition in our industry, and the evolving rules and regulations applicable to digital assets, tokenization and our industry. You should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made, and Bullish undertakes no duty to update these forward-looking statements.

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) — At the end of the settlement date of September 15, 2026, short interest in 3,862 Nasdaq Global MarketSM securities totaled 18,116,572,644 shares compared with 18,212,067,019 shares in 3,860 Global Market issues reported for the prior settlement date of August 31, 2026. The mid-September short interest represents 3.55 days compared with 3.52 days for the prior reporting period.

Short interest in 1,654 securities on The Nasdaq Capital MarketSM totaled 4,404,738,050 shares at the end of the settlement date of September 15, 2026, compared with 4,373,853,400 shares in 1,655 securities for the previous reporting period. This represents a 1.76 day average daily volume; the previous reporting period’s figure was 1.61.

In summary, short interest in all 5,516 Nasdaq® securities totaled 22,521,310,694 shares at the September 15, 2026 settlement date, compared with 5,515 issues and 22,585,920,419 shares at the end of the previous reporting period. This is 2.96 days average daily volume, compared with an average of 2.86 days for the prior reporting period.

The open short interest positions reported for each Nasdaq security reflect the total number of shares sold short by all broker/dealers regardless of their exchange affiliations. A short sale is generally understood to mean the sale of a security that the seller does not own or any sale that is consummated by the delivery of a security borrowed by or for the account of the seller.

For more information on Nasdaq Short interest positions, including publication dates, visit
https://www.nasdaq.com/market-activity/quotes/short-interest
or http://www.nasdaqtrader.com/asp/short_interest.asp.

About Nasdaq:
Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.     

NDAQO

Nasdaq

Media Contact:
Sam Raffalli
sam.raffalli@nasdaq.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4272a2c4-7b47-4f7f-89b4-aed82307a8a7

REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026.

Tumor HI

  • upLIFT, a Phase 3, single-arm, open label study in up to 16 hospitalized participants for the treatment of tumor HI, is ongoing.
    • Enrollment is in progress and topline results are expected before the end of 2026.
  • In June 2026, the Company shared positive interim data from the upLIFT study, announcing that of the 8 participants enrolled, 6 had already met the responder criterion for the study’s primary endpoint within the 8-week pivotal treatment phase. Each of these 6 participants also achieved a complete discontinuation of intravenous glucose requirements with the administration of ersodetug. Since the time of this announcement, the seventh participant has also met the responder criterion for the study’s primary endpoint.
    • One of the 8 enrolled participants withdrew study consent and discontinued ersodetug and all other non-palliative therapies prior to completion of the pivotal treatment phase. This patient had Stage 4 metastatic colon cancer and a poor Eastern Cooperative Oncology Group performance status (ECOG 4). The participant elected to be discharged from the hospital to receive hospice care at home, where they died one week later due to cancer progression. The reduction and eventual discontinuation of intravenous glucose were undertaken in the setting of hospice transition, so the participant is being counted as a non-responder for purposes of assessing the primary endpoint.
  • In June 2026 at the Annual Meeting of the Endocrine Society (ENDO), Rezolute delivered a poster presentation highlighting favorable outcomes from a case series report of 9 patients with refractory hypoglycemia due to malignant insulinoma and non-islet cell tumors (tumor HI), demonstrating that 75% of the patients receiving IV dextrose/total parenteral nutrition (TPN) in the EAP achieved a complete discontinuation of IV dextrose/TPN.
    • The outcomes of this case series were also recently published in manuscript form in The Journal of Clinical Endocrinology & Metabolism (JCEM), titled Ersodetug for refractory hypoglycemia due to malignant insulin-secreting tumors.

Congenital HI

  • In September 2026, the Company provided an update that data from the Phase 3 sunRIZE study in congenital HI, which did not meet its primary endpoint, remains under review with the U.S. Food and Drug Administration (FDA or Agency).
    • In June 2026, the Company provided additional study data for the Agency’s independent review, including source and analysis datasets and summary results from a substantial number of pre-specified, post-hoc, and sensitivity analyses with a focus on continuous glucose monitoring (CGM) based glucose outcomes from the pivotal portion of the study.
    • The open-label extension (OLE) phase of the sunRIZE study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in the use of background standard of care therapies.
    • Rezolute will continue to await feedback and reserves the ability to request a formal meeting under a regulatory timeline, as needed.
  • In June 2026 at ENDO, Rezolute delivered three data presentations focused on congenital HI.
    • In an oral presentation, Huseyin Demirbilek, M.D., Professor, Department of Pediatric Endocrinology, Hacettepe University Faculty of Medicine, Ankara, Turkey, and Principal Investigator of the Phase 3 sunRIZE study, reviewed previously reported results from the study.
    • Two poster presentations highlighted results from systematic analyses of natural history and adverse neurologic and health-economic outcomes resulting from congenital HI, using a meta-analysis of the literature as well as a claims-based approach to quantifying congenital HI complications, respectively.

Fourth Quarter and Full Year Fiscal 2026 Financial Results

Cash, cash equivalents and investments in marketable securities were $107.8 million as of June 30, 2026, compared with $167.9 million as of June 30, 2025.

Research and development (R&D) expenses were $14.9 million for the fourth quarter of fiscal 2026, compared with $20.9 million for the same period a year ago. Full fiscal year 2026 R&D expenses were $53.8 million, compared to $61.5 million in fiscal year 2025. The decrease from fiscal year 2025 to fiscal year 2026 was primarily due to decreased manufacturing costs for ersodetug, partially offset by increased employee-related stock-based compensation expense. R&D expenses include $6.5 million of share-based compensation expense for the fiscal year 2026, compared with $3.5 million for fiscal year 2025.

General and administrative (G&A) expenses were $6.7 million for the fourth quarter of fiscal 2026, compared with $5.0 million for the same period a year ago. Full fiscal year 2026 G&A expenses were $29.2 million, compared to $18.4 million in fiscal year 2025. The increase was primarily attributable to increased employee-related stock-based compensation expense, and an increase in professional fees in preparation for future ersodetug commercial activities. G&A expenses include $8.0 million of share-based compensation expense for fiscal 2026, compared with $3.6 million for fiscal year 2025.

Net loss was $20.5 million for the fourth quarter of fiscal 2026 compared with a net loss of $24.4 million for the same period a year ago. Full year fiscal 2026 net loss was $77.6 million compared to net loss of $74.4 million for the fiscal year 2025.

About Ersodetug

Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of hyperinsulinism (HI), including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia. Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority. 

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com. 

Forward-Looking Statements

This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. These forward-looking statements include, but are not limited to, the potential efficacy of ersodetug in treating hypoglycemia as well as our ability to complete enrollment of the upLIFT study this year and announce topline results. Our ability to predict results or our plans or strategies is inherently uncertain. Notably, no assurance can be given that FDA will agree with the Company that there is evidence of clinically meaningful benefit observed in the sunRIZE study and accordingly the Agency could make the determination that the only path forward for the congenital HI indication is a new randomized control trial similar to sunRIZE. Should the Agency make such a determination, that would adversely impact the Company’s ability to further pursue that indication as well as the commercial potential for ersodetug. Actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. 

Rezolute Contacts:

Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
cmckim@rezolutebio.com
336-608-9706

Rezolute, Inc.
Condensed Consolidated Financial Statements Data
(in thousands, except per share data)
               
  Three Months Ended   Year Ended
  June 30,   June 30,
    2026       2025       2026       2025  
Condensed Consolidated Statements of Operations Data:              
               
Operating expenses:              
Research and development $ 14,889     $ 20,863     $ 53,798     $ 61,527  
General and administrative   6,673       4,987       29,168       18,367  
Total operating expenses   21,562       25,850       82,966       79,894  
Loss from operations   (21,562 )     (25,850 )     (82,966 )     (79,894 )
Non-operating income, net   1,071       1,460       5,380       5,482  
Net loss $ (20,491 )   $ (24,390 )   $ (77,586 )   $ (74,412 )
               
Basic and diluted net loss per common share $ (0.20 )   $ (0.26 )   $ (0.75 )   $ (0.98 )
               
Shares used to compute basic and diluted net loss per common share   104,488       94,340       103,907       75,999  
               
  June 30,   June 30,        
    2026       2025          
               
Condensed Consolidated Balance Sheets Data:              
Cash and cash equivalents $ 10,615     $ 94,107          
Investments in marketable debt securities   97,186       73,751          
Working capital   99,093       159,233          
Total assets   112,849       175,490          
Accumulated deficit   (481,442 )     (403,856 )        
Total stockholders’ equity   100,687       162,127          

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.